Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue
Amgen's quarterly revenue swings between $8.1B and $10.1B, while Vertex climbs steadily from $2.8B to $3.3B—a tale of scale versus trajectory.
Amgen, a major pharmaceutical company, focuses on oncology and cardiovascular diseases, while Vertex Pharmaceuticals specializes in cystic fibrosis treatments. Both companies experienced a seasonal revenue increase in the fourth quarter, due to patients filling their prescriptions after resetting their health insurance deductibles.
Vertex Pharmaceuticals recently acquired Crinetics Pharmaceuticals, and its FDA expanded the use of Casgevy to include patients as young as two years old. The FDA also granted Breakthrough Therapy Designation for a new cystic fibrosis treatment, which could potentially generate $4 billion to $7 billion in annual sales. Amgen, on the other hand, has six drug franchises that generate over $1 billion in annual revenue, and recently reached an agreement with the U.S. government to lower drug prices by approximately 60% to 80%.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
